From a major overall survival breakthrough with tarlatamab-based maintenance therapy in small cell lung cancer to direct evidence of superiority among KRAS G12C inhibitors and new strategies targeting MET-mediated resistance, ESMO Congress 2026 has delivered important developments across thoracic oncology. Yet the meeting also reinforced a fundamental lesson: improvements in progression-free survival do not automatically establish longer overall survival, and promising treatment strategies must be judged against increasingly effective contemporary standards.
Held in Madrid from October 23–27, ESMO Congress 2026 presented pivotal randomized phase III data, mature survival analyses, and emerging biomarker-driven strategies that could reshape lung cancer treatment.
The most consequential findings extended across EGFR-mutated non-small cell lung cancer (NSCLC), KRAS G12C-driven disease, antibody-drug conjugates (ADCs), immunotherapy combinations, extensive-stage small cell lung cancer (ES-SCLC), and potentially curable early-stage disease.
Several studies demonstrated statistically significant overall survival benefits, strengthening the rationale for future changes in treatment standards. Others showed impressive disease-control advantages but remain dependent on mature survival data, regulatory decisions, or validation against established treatment options.
For practicing oncologists, the question after ESMO 2026 is not simply which new therapy performed best, but where it belongs in an increasingly complex treatment sequence, and which results justify changing practice today.
Small Cell Lung Cancer: DeLLphi-305 Introduces a Major Survival Advance
One of the most striking findings at ESMO 2026 came from the phase III DeLLphi-305 trial, evaluating tarlatamab plus durvalumab as first-line maintenance therapy for extensive-stage small cell lung cancer.
Presented by Jacob Sands and simultaneously published in The New England Journal of Medicine, the trial enrolled 563 patients whose disease had not progressed after initial durvalumab plus platinum–etoposide chemotherapy. Patients were randomized to receive maintenance tarlatamab plus durvalumab or durvalumab alone.
At the prespecified interim analysis, median overall survival (OS), measured from maintenance randomization, reached 21.1 months with tarlatamab plus durvalumab versus 12.7 months with durvalumab alone, corresponding to a 58% reduction in the hazard of death (HR 0.42; 95% CI 0.32–0.54; p<0.001).
Median progression-free survival (PFS) was also substantially prolonged, from 1.9 to 7.4 months (HR 0.34; 95% CI 0.28–0.42; p<0.001). These results are particularly important in ES-SCLC, where therapeutic progress has historically been limited and most patients relapse rapidly after first-line treatment.
Tarlatamab is a bispecific T-cell engager targeting delta-like ligand 3 (DLL3) on tumor cells and CD3 on T cells, enabling immune-mediated tumor cell killing. The DeLLphi-305 findings suggest that bringing T-cell-engaging therapy into the maintenance setting may substantially improve survival before clinical relapse.
However, the treatment introduces additional practical and safety considerations. Cytokine release syndrome occurred in nearly half of patients receiving the combination, predominantly at grade 1 or 2. Grade ≥3 adverse events were reported in 46.8% versus 40.6%.
These toxicities require appropriate clinical infrastructure, monitoring, and experience with T-cell-engaging therapies.
What changes after ESMO 2026 is the evidence supporting earlier use of DLL3-directed therapy. DeLLphi-305 provides compelling randomized survival data and could substantially alter maintenance treatment for eligible patients, subject to regulatory authorization and implementation requirements.
Read About DeLLphi-305 Trial on OncoDaily
KRAS G12C: Krascendo 1 Demonstrates That Inhibitors Within the Same Class Are Not Interchangeable
The phase III Krascendo 1 trial represents another important development in targeted therapy. Presented by Ferdinandos Skoulidis, the study directly compared the next-generation KRAS G12C inhibitor divarasib with established KRAS G12C inhibitors, sotorasib or adagrasib, in previously treated advanced NSCLC.
Among 338 randomized patients, median PFS was 9.8 months with divarasib versus 5.7 months with control treatment (HR 0.58; 95% CI 0.44–0.76; p<0.0001).
Importantly, the advantage extended to overall survival. Median OS was 17.7 versus 12.0 months, corresponding to a 44% reduction in the hazard of death (HR 0.56; 95% CI 0.41–0.78; p=0.0005).
Confirmed objective response rates were 58.4% with divarasib versus 32.3% with control treatment, while median duration of response was 11.9 versus 6.9 months. The safety findings were also clinically relevant. Grade 3–4 treatment-related adverse events occurred in 24.6% of patients receiving divarasib compared with 34.5% in the control arm.
The major strength of Krascendo 1 lies in its active comparator design. Unlike studies demonstrating that KRAS G12C inhibition is superior to chemotherapy, Krascendo 1 directly evaluated whether one inhibitor can outperform another targeting the same molecular alteration.
However, approximately 91% of patients in the control arm received sotorasib, limiting definitive conclusions about superiority over adagrasib individually. The trial nevertheless establishes an important principle: molecularly targeted agents directed against the same oncogenic driver should not automatically be regarded as therapeutically equivalent.
After ESMO 2026, KRAS G12C treatment selection is increasingly becoming a question of comparative efficacy, tolerability, durability, and sequencing, not merely target availability. Divarasib’s integration into routine practice will depend on regulatory decisions and access.
Read About Krascendo 1 Trial on OncoDaily
EGFR-Mutated NSCLC: SAFFRON Validates MET-Directed Treatment After Osimertinib Resistance
The phase III SAFFRON trial provided compelling evidence for a molecularly selected treatment strategy after progression on osimertinib.
Presented by Shun Lu, the study evaluated continued EGFR inhibition with osimertinib combined with the selective MET inhibitor savolitinib in patients with EGFR-mutated, MET-overexpressed and/or MET-amplified advanced NSCLC.
Among 338 randomized patients, median PFS reached 7.6 months with osimertinib plus savolitinib versus 5.4 months with platinum–pemetrexed chemotherapy (HR 0.55; 95% CI 0.42–0.72; p<0.001). Median OS was 17.8 versus 12.9 months, representing a 4.9-month difference and a statistically significant 32% reduction in the hazard of death (HR 0.68; 95% CI 0.50–0.91; p=0.010).
Objective response rates were 51% versus 27%, respectively. These findings are important because MET amplification is an established mechanism of resistance to EGFR tyrosine kinase inhibitors.
SAFFRON demonstrates that identifying a relevant resistance mechanism and directing treatment toward that pathway can improve both progression-free and overall survival. However, patient selection was stringent. MET overexpression required IHC 3+ staining in at least 90% of tumor cells, while amplification was defined by at least 10 MET gene copies using fluorescence in situ hybridization.
Consequently, the findings should not be generalized to patients with lower MET expression or less clearly defined resistance mechanisms. Another important limitation is the comparator.
SAFFRON evaluated dual EGFR/MET inhibition against chemotherapy, not against amivantamab-containing regimens or other contemporary post-osimertinib strategies. The trial therefore supports a targeted treatment option for a specific biomarker-defined population without establishing the optimal sequence among available treatments.
The practical message is clear: molecular reassessment at osimertinib progression is becoming increasingly essential. Identifying MET overexpression or amplification may directly influence subsequent treatment selection.
Read About SAFFRON Trial on OncoDaily
SANOVO: Should MET Inhibition Begin Before Resistance Develops?
While SAFFRON investigated MET-directed therapy after acquired resistance, the phase III SANOVO trial addressed a different question: can upfront suppression of MET signaling improve first-line treatment outcomes in patients whose tumors already demonstrate MET overexpression?
Presented by Yi-Long Wu, SANOVO enrolled 326 treatment-naïve patients with advanced EGFR-mutated, MET-overexpressing NSCLC across centers in China. Patients received savolitinib plus osimertinib or osimertinib alone.
In the MET IHC 3+ population, median PFS was 24.8 versus 11.1 months, corresponding to a 55% reduction in the hazard of progression or death (HR 0.45; 95% CI 0.31–0.66; p<0.0001). In the overall intention-to-treat population, median PFS was 24.9 versus 13.8 months (HR 0.56; 95% CI 0.43–0.74; p<0.0001).
The overall survival results were also encouraging, with median OS of 44.5 months versus 34.9 months and an HR of 0.48 (95% CI 0.33–0.68). However, OS maturity was approximately 40.5%, and confirmatory statistical significance for this secondary endpoint was not established in the reported analysis.
The clinical trade-off was substantial. Grade ≥3 treatment-emergent adverse events occurred in 77.2% with savolitinib plus osimertinib versus 38.4% with osimertinib alone. Serious adverse events and treatment discontinuations were also considerably more frequent with combination therapy.
These findings support a potentially important first-line strategy but do not establish that all patients with EGFR-mutated disease should receive dual EGFR/MET inhibition. SANOVO was conducted exclusively in China, used specific MET IHC thresholds, and did not directly compare the combination against other contemporary first-line intensification approaches.
Together, SAFFRON and SANOVO illustrate an important evolution in precision oncology: MET-directed therapy may have a role both in overcoming acquired resistance and in selecting upfront treatment for tumors with relevant baseline molecular characteristics.
The remaining challenge is identifying which patients derive enough additional benefit to justify prolonged dual inhibition and increased toxicity.
Read About SANOVO Trial on OncoDaily
Antibody-Drug Conjugates: OptiTROP-Lung06 Challenges Chemotherapy in the First Line
One of the most important ADC presentations came from the phase III OptiTROP-Lung06 trial, evaluating sacituzumab tirumotecan (sac-TMT) plus pembrolizumab versus platinum-based chemotherapy plus pembrolizumab.
The study enrolled 455 patients with previously untreated advanced nonsquamous NSCLC, PD-L1 expression below 1%, and no actionable genomic alterations. Presented by Caicun Zhou, the prespecified interim analysis demonstrated median PFS of 15.0 months with sac-TMT plus pembrolizumab versus 5.7 months with chemoimmunotherapy.
The corresponding HR was 0.49 (95% CI 0.36–0.65; p<0.001), indicating a 51% reduction in the hazard of progression or death. Importantly, objective response rates were relatively similar, at 50.2% versus 47.3%.
However, responses were substantially more durable with sac-TMT, with median duration of response reaching 13.6 months compared with 6.8 months. These findings suggest that the principal advantage may be prolonged disease control rather than a substantially higher probability of initial tumor response.
Grade ≥3 treatment-emergent adverse events were reported in 47.6% with the ADC-based combination versus 60.6% with chemotherapy plus pembrolizumab. Overall survival data remained immature, with a favorable numerical HR of 0.58.
OptiTROP-Lung06 represents an important conceptual development because it directly challenges the chemotherapy component of standard first-line chemoimmunotherapy. Rather than adding another cytotoxic agent to an already intensive regimen, the study evaluates replacement of conventional chemotherapy with an ADC.
However, the trial was conducted in a defined PD-L1-negative nonsquamous population, and its results should not be generalized to all first-line NSCLC.
The potential change is substantial: ADCs may increasingly compete with conventional chemotherapy as the cytotoxic backbone of immunotherapy combinations. Whether this translates into broader treatment standards will depend on mature OS, toxicity, accessibility, and confirmation across diverse populations.
Read About OptiTROP-Lung06 Ttial on OncoDaily
Post-EGFR Progression: Two ADC Strategies Expand the Treatment Landscape
The ADC advances extended beyond first-line treatment. In the final OS analysis of the phase III OptiTROP-Lung04 trial, sacituzumab tirumotecan demonstrated a sustained survival advantage over platinum-based chemotherapy in EGFR-mutated NSCLC after EGFR-TKI progression.
Median OS was 25.9 versus 17.4 months, representing an 8.5-month difference and an HR of 0.69 (95% CI 0.54–0.89). At two years, estimated OS was 54.1% with sac-TMT compared with 37.2% with chemotherapy.
The survival advantage remained favorable after adjustment for subsequent ADC therapy, although such analyses remain dependent on statistical assumptions. Another major result came from the phase III PANKU-Lung01 trial, evaluating izalontamab brengitecan, a bispecific EGFR/HER3-directed ADC, after progression on third-generation EGFR inhibition.
Median PFS was 11.1 months with izalontamab brengitecan versus 5.7 months with platinum chemotherapy (HR 0.40; 95% CI 0.31–0.51; p<0.0001). Confirmed response rates were 60.2% versus 34.5%, while median duration of response reached 10.4 versus 5.7 months. Overall survival remained immature.
Together, these findings demonstrate that ADC development is becoming particularly competitive in post-EGFR NSCLC, where acquired resistance often involves heterogeneous molecular mechanisms.
Unlike highly selective inhibitors targeting a specific resistance alteration, ADCs may provide activity across broader tumor populations through cell-surface antigen targeting and intracellular payload delivery. Nevertheless, the increasing number of active treatments creates uncertainty about optimal sequencing.
There are no definitive head-to-head comparisons establishing the superiority of sac-TMT, izalontamab brengitecan, or other ADCs over each other or over all available antibody-based and targeted combinations.
Prior treatment exposure, payload-related cross-resistance, interstitial lung disease, hematologic toxicity, and regulatory access will become increasingly relevant.
PD-L1-High NSCLC: PERSEE Reopens the Immunotherapy Intensification Debate
The phase III PERSEE trial addressed a long-standing question in metastatic NSCLC: should patients with PD-L1 expression ≥50% receive pembrolizumab alone or pembrolizumab combined with platinum-based chemotherapy?
The randomized study enrolled 321 patients with previously untreated advanced NSCLC and high PD-L1 expression. At a median follow-up of 38.7 months, median PFS was 16.1 months with pembrolizumab plus chemotherapy versus 6.9 months with pembrolizumab alone.
The HR was 0.56 (95% CI 0.43–0.74; p<0.001). Median OS was numerically longer at 50.2 versus 29.9 months, but the HR was 0.77 (95% CI 0.56–1.05), without a statistically significant OS advantage.
The increased disease control came at the cost of substantially greater toxicity. Grade ≥3 treatment-related adverse events occurred in 54% of patients receiving combination treatment compared with 19% receiving pembrolizumab monotherapy.
These findings support the efficacy of chemotherapy intensification, particularly in patients where rapid tumor control may be clinically important. However, they do not establish that every patient with high PD-L1 expression should receive chemotherapy alongside pembrolizumab.
The choice remains dependent on symptoms, tumor burden, disease tempo, comorbidities, expected toxicity, and individual patient priorities. PERSEE reinforces a broader theme from ESMO 2026: more intensive therapy may improve PFS substantially without demonstrating a statistically confirmed OS advantage.
Read About PERSEE Trial on OncoDaily
Early-Stage NSCLC: KEYNOTE-091 Challenges the Assumption That DFS Always Predicts Survival
The final analysis of the phase III PEARLS/KEYNOTE-091 trial provided an important long-term perspective on adjuvant pembrolizumab in completely resected stage IB–IIIA NSCLC. Presented by Mary E. O’Brien, the study evaluated approximately one year of pembrolizumab versus placebo after surgery, with adjuvant chemotherapy administered when indicated.
After a median follow-up of 87.7 months, median disease-free survival (DFS) remained favorable with pembrolizumab at 58.7 versus 43.3 months (HR 0.85; 95% CI 0.73–0.98). However, six-year DFS was 44.0% versus 39.2%, representing a relatively modest absolute difference of 4.8 percentage points.
More importantly, no statistically significant overall survival improvement was demonstrated. Six-year OS was 68.5% with pembrolizumab versus 66.4% with placebo, with an HR of 0.98 (95% CI 0.81–1.18; p=0.41826). The final analysis therefore confirms a persistent DFS advantage without establishing a corresponding survival benefit.
These findings do not invalidate the established role of adjuvant pembrolizumab in appropriately selected patients. However, they strengthen the importance of distinguishing recurrence prevention from proven survival extension.
In potentially curable disease, that distinction is especially relevant because additional systemic therapy exposes patients to toxicity even when some may already be cured by surgery and chemotherapy.
After ESMO 2026, treatment discussions should place greater emphasis on absolute recurrence risk, established evidence, long-term toxicity, and the evolving role of neoadjuvant and perioperative immunotherapy.
Molecular Residual Disease: MDT-BRIDGE Shows the Promise and Limits of ctDNA-Guided Treatment
The phase II MDT-BRIDGE trial introduced further evidence supporting circulating tumor DNA (ctDNA) as a potential marker of treatment response during neoadjuvant chemoimmunotherapy.
Presented by Jonathan Spicer, the exploratory analysis used an ultrasensitive, tumor-informed assay in patients with resectable or borderline resectable stage IIB–IIIB NSCLC receiving durvalumab plus platinum-based chemotherapy.
Baseline ctDNA was detectable in 99.1% of biomarker-evaluable patients. After just one treatment cycle, ctDNA clearance had a positive predictive value of 83.3% for pathological complete response, although the estimate was based on only six patients with early molecular clearance.
Before surgery, ctDNA clearance was observed in 76.0% of patients achieving pathological complete response versus 20.9% of those without complete response.
Among resected patients, none of the 28 patients with presurgical ctDNA clearance experienced an event-free survival event during available follow-up, compared with five events among 40 patients without clearance.
These findings strengthen the biological and prognostic rationale for molecular monitoring during neoadjuvant treatment. However, they remain exploratory and cannot establish that changing treatment based on ctDNA results improves outcomes.
ctDNA clearance is not yet a validated reason to omit surgery, reduce adjuvant therapy, or alter definitive local treatment.
The potential clinical change is therefore prospective rather than immediate: future treatment strategies may increasingly combine imaging, pathological response, and molecular residual disease assessment to guide individualized treatment intensity.
Read About MDT-BRIDGE Trial on OncoDaily
Oligometastatic NSCLC: SARON Improves Disease Control Without Extending Survival
The randomized phase II SARON trial evaluated whether adding consolidative radiotherapy to systemic treatment could improve outcomes in patients with synchronous oligometastatic NSCLC without actionable genomic alterations.
Median PFS increased from 8.9 to 13.9 months with the addition of radiotherapy (HR 0.64; 95% CI 0.43–0.95; p=0.03). Local disease control also improved. However, the trial did not meet its primary OS endpoint.
Median OS was 31 months with consolidative radiotherapy versus 28 months with systemic therapy alone, with an HR of 0.99 (95% CI 0.63–1.55; p=0.95).
These results demonstrate that improved local control and delayed progression do not necessarily translate into longer overall survival.
SARON does not eliminate the role of local consolidation in carefully selected oligometastatic patients, particularly where symptom control, prevention of local complications, or durable local control are relevant.
However, the findings do not support routine use of consolidative radiotherapy with the expectation of improving OS across the broader eligible population.
Read About SARON Trial on OncoDaily
Negative ADC Evidence: SigVie-002 Emphasizes the Importance of Confirmatory Endpoints
The phase III SigVie-002 trial provided an important counterpoint to the positive ADC findings. The study evaluated sigvotatug vedotin, an integrin β6-directed ADC, versus docetaxel in previously treated advanced nonsquamous NSCLC.
The primary OS endpoint was negative. Median OS was 11.9 versus 11.5 months, respectively, with an HR of 0.929 (95% CI 0.767–1.126; one-sided p=0.226). Median PFS was also not significantly improved in the overall population.
Although a post hoc second-line subgroup analysis identified a favorable PFS signal, this finding remains hypothesis-generating and cannot reverse the negative primary result.
SigVie-002 reinforces an essential principle as ADC development accelerates: promising early antitumor activity does not guarantee a positive phase III survival outcome. Patient selection, optimal treatment line, target expression, payload activity, and toxicity must all be evaluated through appropriately designed confirmatory trials.
Read About SigVie-002 Trial on OncoDaily
What Should Oncologists Actually Change After ESMO 2026?
The most important developments from ESMO 2026 fall into distinct categories. DeLLphi-305 and Krascendo 1 provide particularly compelling randomized survival evidence for new therapeutic strategies. DeLLphi-305 supports earlier use of DLL3-directed T-cell engagement in eligible ES-SCLC patients, while Krascendo 1 establishes clinically meaningful differences among KRAS G12C inhibitors.
SAFFRON strengthens the clinical value of identifying MET-mediated resistance after osimertinib progression. SANOVO extends that biological concept into the first-line setting, although increased toxicity and the need for broader validation complicate immediate application.
OptiTROP-Lung06, OptiTROP-Lung04, and PANKU-Lung01 demonstrate that ADCs are moving beyond heavily pretreated populations and increasingly challenging conventional chemotherapy-containing regimens.
In contrast, PERSEE, PEARLS/KEYNOTE-091, and SARON highlight the limitations of interpreting PFS or DFS improvements without corresponding evidence of prolonged survival. Finally, MDT-BRIDGE illustrates how biomarker-guided treatment may evolve, with molecular response monitoring potentially complementing anatomical and pathological assessment.
Across these studies, one principle is becoming increasingly clear: treatment selection in lung cancer is shifting toward a more individualized integration of molecular characteristics, resistance mechanisms, prior treatment exposure, disease stage, CNS involvement, toxicity, and patient preferences.
The next challenge is no longer simply expanding the number of effective therapies, but determining when and in whom each should be used.
OncoDaily Takeaway
ESMO Congress 2026 represents an important transition in lung oncology, with several treatment strategies demonstrating meaningful survival gains while others expose the limitations of conventional assumptions about disease control and treatment intensification.
The DeLLphi-305 findings stand among the most consequential developments, introducing a substantial overall survival benefit with tarlatamab plus durvalumab as maintenance therapy in extensive-stage small cell lung cancer. Krascendo 1 similarly advances precision oncology by demonstrating that a next-generation KRAS G12C inhibitor can outperform established agents within the same class in both progression-free and overall survival.
The EGFR-mutated treatment landscape is becoming increasingly biomarker-driven. SAFFRON validates targeting MET-mediated resistance after osimertinib progression, while SANOVO raises the possibility that baseline MET expression could support earlier dual-pathway inhibition. The clinical challenge will be identifying those most likely to benefit while limiting unnecessary treatment-related toxicity.
The ADC field is moving rapidly toward earlier treatment lines. OptiTROP-Lung06 challenges conventional chemoimmunotherapy in PD-L1-negative nonsquamous NSCLC, while OptiTROP-Lung04 and PANKU-Lung01 expand options after EGFR-targeted treatment. However, comparative sequencing, cross-resistance, mature survival outcomes, and long-term safety remain unresolved.
Equally important were the trials that did not establish a survival benefit. PERSEE, PEARLS/KEYNOTE-091, SARON, and SigVie-002 demonstrate why oncologists must distinguish statistically significant disease-control improvements, exploratory subgroup signals, and genuinely confirmed survival advantages.
The most important change after ESMO 2026 is not simply the arrival of more drugs. It is the growing ability and responsibility, to match treatment intensity, mechanism of action, and timing to the biological and clinical characteristics of each patient’s disease.
The next era of lung oncology will be defined by earlier identification of actionable resistance pathways, more rational sequencing of targeted agents and ADCs, integration of immunotherapy with novel immune-engaging platforms, and increasingly individualized treatment decisions supported by mature clinical outcomes.
Source
Selected presentations and peer-reviewed publications from ESMO Congress 2026, Madrid, Spain, October 23–27, 2026:
- Sands J, et al. DeLLphi-305: Tarlatamab plus durvalumab maintenance in ES-SCLC. LBA3. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2609482.
- Skoulidis F, et al. Krascendo 1: Divarasib versus sotorasib or adagrasib in KRAS G12C-mutated NSCLC. LBA5. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2605703.
- Lu S, et al. SAFFRON: Osimertinib plus savolitinib after osimertinib progression. LBA6. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2611335.
- Wu YL, et al. SANOVO: Savolitinib plus osimertinib in first-line EGFR-mutated, MET-overexpressing NSCLC. LBA69.
- Zhou C, et al. OptiTROP-Lung06: Sacituzumab tirumotecan plus pembrolizumab. LBA66. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2611280.
- Fang W, et al. OptiTROP-Lung04 final overall survival analysis. LBA67.
- Zhang L, et al. PANKU-Lung01: Izalontamab brengitecan versus chemotherapy after EGFR-TKI progression. LBA71.
- PERSEE (GFPC 01-2020): Pembrolizumab with or without chemotherapy in PD-L1-high advanced NSCLC. Abstract 2614O.
- O’Brien ME, et al. PEARLS/KEYNOTE-091 final analysis. Abstract 2511O.
- Spicer J, et al. MDT-BRIDGE ctDNA clearance analysis. ESMO 2026 rapid oral presentation.
- McDonald F, et al. SARON: Consolidative radiotherapy in oligometastatic NSCLC. Abstract 2613O.
- SigVie-002: Sigvotatug vedotin versus docetaxel in previously treated NSCLC. ESMO 2026.
